Expression of Osteopontin in oesophageal squamous cell carcinoma

被引:0
|
作者
Y Kita
S Natsugoe
H Okumura
M Matsumoto
Y Uchikado
T Setoyama
T Owaki
S Ishigami
T Aikou
机构
[1] Field of Oncology,Department of Surgical Oncology and Digestive Surgery
[2] Course of Advanced Therapeutics,undefined
[3] Graduate School of Medical and Dental Science,undefined
[4] Kagoshima University,undefined
来源
British Journal of Cancer | 2006年 / 95卷
关键词
osteopontin; oesophageal cancer; immunohistochemical staining; prognosis; lymph node metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
Osteopontin is a multifunctional 34 kDa extracellular matrix protein with a cell-binding domain. It is involved cell adhesion and cell migration and is therefore considered to influence tumorigenesis and/or metastasis. The purpose of the present study was to evaluate the clinical significance of Osteopontin expression in oesophageal squamous cell carcinoma (ESCC). In the present study, we immunohistochemically investigated the relationship between Osteopontin expression and clinicopathological factors including prognosis in surgical specimens of primary tumours in 175 patients with ESCC. Osteopontin was expressed in 48% of 175 patients. Osteopontin expression was significantly correlated with lymph node metastasis, lymphatic invasion, and stage (P=0.0015, 0.037 and 0.033, respectively). Tumours with expressing Osteopontin exhibited more lymph node metastasis, lymphatic invasion and advanced stage than the tumour with negative Osteopontin expression. Five-year survival rate was better in patients with negative Osteopontin expression than in those with positive Osteopontin expression (P=0.035). However, multivariate analysis revealed that Osteopontin expression was not an independent prognostic factor. As our findings suggest that Osteopontin may play an important role in progress of ESCC, the evaluation of Osteopontin expression is useful for predicting the malignant properties of ESCC.
引用
收藏
页码:634 / 638
页数:4
相关论文
共 50 条
  • [21] Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma
    Gotoda, T
    Matsumura, Y
    Kondo, H
    Ono, H
    Kanamoto, A
    Kato, H
    Watanabe, H
    Tachimori, Y
    Nakanishi, Y
    Kakizoe, T
    GUT, 2000, 46 (01) : 14 - 19
  • [22] P-glycoprotein expression in human oesophageal squamous carcinoma cell lines
    Zampierl, L
    Veale, RB
    SOUTH AFRICAN JOURNAL OF SCIENCE, 2001, 97 (7-8) : 329 - 333
  • [23] Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma
    Nakajima, M
    Fukuchi, M
    Miyazaki, T
    Masuda, N
    Kato, H
    Kuwano, H
    BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1734 - 1739
  • [24] Toripalimab and chemotherapy in oesophageal squamous cell carcinoma
    不详
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (5) : 280 - 280
  • [25] Oesophageal squamous cell carcinoma in two cats
    Gualtieri, M
    Monzeglio, MG
    Di Giancamillo, M
    JOURNAL OF SMALL ANIMAL PRACTICE, 1999, 40 (02) : 79 - 83
  • [26] Nivolumab for chemorefractory oesophageal squamous cell carcinoma
    Chenard-Poirier, Maxime
    Smyth, Elizabeth C.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S225 - S228
  • [27] Carbonyl Metabolism in Oesophageal Squamous Cell Carcinoma
    Goh, Yan Mei
    Antonowicz, Stefan
    Hanna, George
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 26 - 26
  • [28] Toripalimab and chemotherapy in oesophageal squamous cell carcinoma
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 280 - 280
  • [29] Spontaneous regression of oesophageal squamous cell carcinoma
    Khan, Haroon
    Casey, Patrick
    Hayes, Stephen
    Tokala, Ajay
    Sultan, Javed
    BMJ CASE REPORTS, 2021, 14 (06)
  • [30] Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression
    Takeno, Shinsuke
    Yamashita, Shin-ichi
    Takahashi, Yoshiaki
    Ono, Kiyoshi
    Kamei, Mirei
    Moroga, Toshihiko
    Kawahara, Katsunobu
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2010, 37 (02) : 440 - 445